Management of Menopausal Symptoms: A Review

JAMA. 2023 Feb 7;329(5):405-420. doi: 10.1001/jama.2022.24140.

Abstract

Importance: Menopause, due to loss of ovarian follicular activity without another pathological or physiological cause, typically occurs between the ages of 45 years and 56 years. During the menopausal transition, approximately 50% to 75% of women have hot flashes, night sweats, or both (vasomotor symptoms) and more than 50% have genitourinary symptoms (genitourinary syndrome of menopause [GSM]).

Observations: Vasomotor symptoms typically last more than 7 years and GSM is often chronic. Efficacious treatments for women with bothersome vasomotor symptoms or GSM symptoms include hormonal and nonhormonal options. Systemic estrogen alone or combined with a progestogen reduces the frequency of vasomotor symptoms by approximately 75%. Oral and transdermal estrogen have similar efficacy. Conjugated equine estrogens (CEE) with or without medroxyprogesterone acetate (MPA) were the only hormonal treatments for which clinical trials were designed to examine cardiovascular events, venous thromboembolism, and breast cancer risk. Compared with placebo, the increased risk of stroke and venous thromboembolism associated with CEE (with or without MPA) and breast cancer (with use of CEE plus MPA) is approximately 1 excess event/1000 person-years. Low-dose CEE plus bazedoxifene is not associated with increased risk of breast cancer (0.25%/year vs 0.23%/year with placebo). Bioidentical estrogens approved by the US Food and Drug Administration (with identical chemical structure to naturally produced estrogens, and often administered transdermally) also are available to treat vasomotor symptoms. For women who are not candidates for hormonal treatments, nonhormonal approaches such as citalopram, desvenlafaxine, escitalopram, gabapentin, paroxetine, and venlafaxine are available and are associated with a reduction in frequency of vasomotor symptoms by approximately 40% to 65%. Low-dose vaginal estrogen is associated with subjective improvement in GSM symptom severity by approximately 60% to 80%, with improvement in severity by 40% to 80% for vaginal prasterone, and with improvement in severity by 30% to 50% for oral ospemifene.

Conclusions and relevance: During the menopausal transition, approximately 50% to 75% of women have vasomotor symptoms and GSM symptoms. Hormonal therapy with estrogen is the first-line therapy for bothersome vasomotor symptoms and GSM symptoms, but nonhormonal medications (such as paroxetine and venlafaxine) also can be effective. Hormone therapy is not indicated for the prevention of cardiovascular disease.

Publication types

  • Review

MeSH terms

  • Autonomic Nervous System Diseases* / etiology
  • Estrogen Replacement Therapy* / methods
  • Estrogens / therapeutic use
  • Estrogens, Conjugated (USP) / adverse effects
  • Female
  • Female Urogenital Diseases* / etiology
  • Hot Flashes / drug therapy
  • Hot Flashes / etiology
  • Humans
  • Medroxyprogesterone Acetate / therapeutic use
  • Menopause* / drug effects
  • Neoplasms / drug therapy
  • Paroxetine / pharmacology
  • Sweating
  • Venlafaxine Hydrochloride / pharmacology
  • Venlafaxine Hydrochloride / therapeutic use
  • Venous Thromboembolism / drug therapy
  • Venous Thromboembolism / etiology

Substances

  • Estrogens
  • Estrogens, Conjugated (USP)
  • Medroxyprogesterone Acetate
  • Paroxetine
  • Venlafaxine Hydrochloride